Search research articles
Contact Us
Filters
Showing results (111-120 of 154) with videos related to
Page
of 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study
G Mangili, C Sigismondi, D Lorusso, et al.
British Journal of Cancer
|
May 22, 2008
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
V Adamo, V Lorusso, R Rossello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L Gladieff, A Ferrero, G De Rauglaudre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A González-Martín, P Harter, A Leary, et al.
ESMO Open
|
February 18, 2021
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
R Berardi, M Torniai, M S Cona, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, T J Bosse, C L Creutzberg, et al.
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2010
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
F Caponigro, D Lorusso, G Fornari, et al.
ESMO Open
|
July 18, 2022
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
L Musacchio, C M Cicala, F Camarda, et al.
British Journal of Cancer
|
May 31, 2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
D Lorusso, G Scambia, G Amadio, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 154) with videos related to
Sort By:
Page
of 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study
G Mangili, C Sigismondi, D Lorusso, et al.
British Journal of Cancer
|
May 22, 2008
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
V Adamo, V Lorusso, R Rossello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L Gladieff, A Ferrero, G De Rauglaudre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A González-Martín, P Harter, A Leary, et al.
ESMO Open
|
February 18, 2021
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
R Berardi, M Torniai, M S Cona, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, T J Bosse, C L Creutzberg, et al.
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
Cancer Chemotherapy and Pharmacology
|
May 19, 2010
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
F Caponigro, D Lorusso, G Fornari, et al.
ESMO Open
|
July 18, 2022
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
L Musacchio, C M Cicala, F Camarda, et al.
British Journal of Cancer
|
May 31, 2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
D Lorusso, G Scambia, G Amadio, et al.
Page
of 16